The Ascites Market Size was valued at USD 1.29 Billion in 2023. The global ascites industry is projected to grow from USD 1.36 Billion in 2024 to USD 2.41 Billion by 2032, exhibiting a CAGR of 3.89% during the forecast period (2024 - 2032).
Ascites are abnormal fluid that is gathered in the intestinal chamber. Ascites most generally make the occurrence of liver cirrhosis. Its presence is a gateway to high blood pressure. However, some minorly found factors of ascites are heart failure, kidney failure, cancers, and pancreas infection.
Further, when the ascites become malignant, they become the principal cause of ovarian cancer. Moreover, Malignancy connected to ascites can also notice in tumours of the breast, lung, pancreas, gastric, and liver. The physical examination can track ascites when the volume is higher than 1.5 l. However, ultrasound and CT scans are recommended when the fluid gathering is smaller.
,Sequana Medical announced the substantive review of alfa pump’s Premarket Approval (PMA) application by the United States Food and Drug Administration (US FDA). The company projects an FDA approval in H2 2024.
,OCE-205 was granted Orphan Drug Designation (ODD) by the US FDA for ascites treatment not involving cancer except for etiologies .
, Astellas Pharma revealed that it had executed a licensing deal with Mirati Therapeutics on the development and commercialisation of a drug candidate indicated for ascites. This collaboration is expected to leverage both companies’ capabilities and take the field ahead significantly.
, Gilead Sciences declared that they had completed the acquisition of Principia Biopharma, a company which is developing new ascites treatment. Gilead Science’s resources and expertise are expected to accelerate the market introduction of this treatment, giving hope to patients with this difficult condition.
,Johnson & Johnson entered into a partnership with Arbutus Biopharma in order to develop and commercialize an ascites drug candidate, according to an announcement made on their website . Both companies have combined their assets under this agreement, which should result in significant market advancements due to joint efforts.
Novartis submitted its New Drug Application (NDA) for its ascites drug candidate to FDA. This marks a major progression towards the development of a therapy against this malady.
The scattering cases of the coronavirus pandemic have a great jolt on life around the world. The most affected by COVID-19 are the two departments, i.e., health and economy. Therefore, they have experienced a period of decreased economic activity and depression. The only solution to this crooked situation is to make a blueprint amid this epidemic. According to the report, companies shall aid in the future Ascites market.
In fact, the increasing ubiquity of Cirrhosis, modifications in recompense policies, and amplifying fluke of cancer are the major drivers thrusting the Ascites Market growth. For example, a study shown in the Canadian Journal of Gastroenterology and Hepatology in 2016 describes that almost 75% of Cirrhosis ascites patients are brought to hospitals. Furthermore, in the European Region, Cirrhosis for ascites is found rigorously.
However, the rigid ground rules and problems connected with Ascites treatment, such as interior bleeding after paracentesis treatment and vulnerability to radiation in chemotherapy, may constrain the outgrowth of the Market till the forecast period. For example, research in Experimental and Molecular Medicine in 2017 discussed that the non-malignant liver tissues could also catalyze envenomed due to high radiation. Thus, it will take less the course of therapy, and most importantly, it can create chronic ramifications such as late fibrosis.
There are many opportunities expected in Market during the forecast period. The main emphasis will be given to the improvement of the capacity to persuade the tests are delivering a greater impact on the opportunities for the market.
Challenges are there in lowering the radiations created by chemotherapy. Also, the complications accompanied by ascites treatment can restrain the market's growth.
The key driver, the rising cases of Cirrhosis for ascites, will propel the market's growth as suggested in the Ascites Market forecast. For example, in the American Cancer Society Report in 2018, it is reported that due to cancer, 609,640 deaths happened. In 2016 Nano Antibiotics got LAT pharma LLC. Moreover, it is a popular biotechnology company that makes new medications to battle against the overpowering problem of Cirrhosis.
The increasing Ascites Market because of the rising cases of malignant due to ascites and the introduction of new medicines in biotechnology are some assertive prospects. Basically, the demand for medicines and Diagnoses will increase more in the future and can mutinously improve the market's value chain.
The Ascites Market splintered into types of Diagnosis, Treatment and clients. Moreover, the development among these segments will help you anatomize recess resources of excrescency. So, you can make your game plans to approach the Ascites Market trend and rule on your quick act or practice of employing your strategies on the areas you can distinct target market.
According to types, the market is divided into transudative ascites and exudates ascites.
However, depending on the diagnosis, the Ascites Market size is divided intoÂ
, CT scan, MRI, blood test, laparoscopy, angiography, etc.
Besides, depending on treatment, it is portioned into medication, paracentesis, surgery, etc. Again, medication has various segments: diuretics, special nutrition, and others.
Oral, parental and others are the route of administration segment of Ascites Market. Based on clients, the market splintered into hospitals, specialty clinics, home care, and more. However, the hospital and clinic segment rationalized for Ascites Market revenue of USD 838.4 million.
Moreover, depending on the allotment channel, there are hospital pharmacies, retail pharmacies, online pharmacies and more in the market.
So, the regional analysis of the Ascites Market is mainly based on the market size information known from the country.Consequently, according to Ascites Market Research, America, Europe, Asia Pacific, the Middle East, and Africa are the countries covering this market.
To illustrate, North America holds the largest Ascites Market share because all the main product manufacturers are from here. Furthermore, they have high research and development skills and aced professionals and health care lay.Besides, Europe holds the second largest market because of their increasing liver damage and cancer cases.However, according to the Ascites Market forecast, Asia Pacific will hold the largest market in the future years. It will happen because the Asia Pacific has leviathan development opportunities of Market.
Moreover, because of being a county full of poverty and fewer development opportunities, the Middle East and Africa hold the least market of Ascites.
The competitive landscape of Market provides details about a competitor. Additionally, some of the game plans followed by the key players are creativity, output evolution, obtainment and progress.
Some substantive key players in Ascites Market are:
The report overview of Ascites Market consists:
| Attribute/Metric | Details |
| Market Size 2023 | 1.29 (USD Billion) |
| Market Size 2024 | 1.36 (USD Billion) |
| Market Size 2032 | 2.41 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 3.89 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Â Â Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | BioVie Inc. (US), Fresenius SE & Co. KGaA (Germany), Sequana Medical NV (Switzerland), BD (US), Medtronic (Ireland), PharmaCyte Biotech Inc. (US), and GI Supply (US) |
| Â Â Key Market Opportunities | Improvement of the capacity to persuade the tests |
| Â Â Key Market Drivers | Increasing ubiquity of Cirrhosis, modifications in recompense policies, and amplifying fluke of cancer |
Ascites Market Highlights:
Frequently Asked Questions (FAQ) :
Ascites market projected to grow at approximately 3.89% CAGR during the assessment period (2024-2032).
The valuation of the global ascites market is estimated to increase to USD 2.41 Billion by the end of 2032.
Increasing activities of new drugs development and technological improvements are major tailwinds pushing the growth of the global ascites market.
North America holds the largest share in the global ascites market, followed by Europe and the Asia Pacific, respectively.
BioVie Inc. (US), Fresenius SE & Co. KGaA (Germany), Sequana Medical NV (Switzerland), BD (US), Medtronic (Ireland), PharmaCyte Biotech Inc. (US), and GI Supply (US), are some of the top players operating in the global ascites market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
